Additionally, Ganguly et al. (2021) confirmed that API-loaded galactose-modified PLGA nanoparticles (API-GAL-NPs) exhibited more pronounced therapeutic effects in rats with diethylnitrosamine (DEN)-induced liver cancer. Here, GAL is linked to liver cancer.